Back

Patisiran treatment for ATTR cardiac amyloidosis: 18-month results of the phase 3 APOLLO-B study

20 May 2023 (16:50 - 17:00)
Organised by: Logo
Congress Presentation Part of: Late breaking clinical trials: chronic HF and cardiomyopathies Pharmacotherapy HFA Premium Access Heart Failure 2023 Heart Failure Association (HFA)

About the speaker

Photo
Professor Marianna Fontana

University College London, London (United Kingdom of Great Britain & Northern Ireland)

5 More presentations in this session

Presentation thumbnail
Remote Hemodynamic Monitoring of Pulmonary Artery Pressures in Patients with Chronic Heart Failure (MONITOR-HF): A randomized controlled clinical trial
Professor J. Brugts (Rotterdam, NL)
Slides Video
Presentation thumbnail
Phase 1b evaluation of safety and activity of JK07 in heart failure with reduced ejection fraction
Professor W. Tang (Cleveland, US)
Slides Video
Presentation thumbnail
TRACER-HF: Trientine-HCL for treatment of heart failure and reduced ejection fraction
Professor J. Januzzi (Boston, US)
Slides Video
Presentation thumbnail
REDWOOD-HCM-Cohort 4: Aficamten in non-obstructive HCM
Doctor A. Masri (Portland, US)
Slides Video
Presentation thumbnail
Primary results of the Phase Ib proof-of-concept study of NI006, a recombinant human antibody to deplete amyloid deposits in ATTR-cardiomyopathy
Doctor P. Garcia-Pavia (Majadahonda, ES)
Slides Video

Access the full session

Session thumbnail
Late breaking clinical trials: chronic HF and cardiomyopathies
Video

The Event

Event poster

Heart Failure 2023

20 May 2023 16:50 CET
You may be interested in
thumbnail
Congress Session
Late breaking clinical trials: chronic HF and cardiomyopathies

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources